Payment overview · 2025
General Payments
$113.52
5 reported records · 3 companies
Healthcare provider profile · identity verified
Upinder Kaur Basi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OAKDALE, CA · NPI 1891782009
Verified facts
What the public records show
CMS Open Payments records show Upinder Kaur Basi, MD received $113.52 in general payments during 2025 across 5 reported records.
Abbott Laboratories accounted for 43.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.07 | 43.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.29 | 40.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.16 | 16.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.52 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $49.07 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 849 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 689 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 144 |
| Losartan Potassium | Losartan Potassium | 532 | 125 |
| Gabapentin | Gabapentin | 434 | 83 |
| Furosemide | Furosemide | 397 | 89 |
| Lisinopril | Lisinopril | 335 | 100 |
| Metformin Hcl | Metformin Hcl | 328 | 87 |
| Omeprazole | Omeprazole | 310 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 273 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 257 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 55 |
| Potassium Chloride | Potassium Chloride | 207 | 51 |
| Eliquis | Apixaban | 185 | 32 |
| Glimepiride | Glimepiride | 178 | 47 |
| Tramadol Hcl | Tramadol Hcl | 177 | 32 |
| Sertraline Hcl | Sertraline Hcl | 174 | 37 |
| Simvastatin | Simvastatin | 172 | 42 |
| Azithromycin | Azithromycin | 164 | 124 |
| Jardiance | Empagliflozin | 163 | 35 |
| Alprazolam | Alprazolam | 162 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 150 | 23 |
| Carvedilol | Carvedilol | 149 | 30 |
| Montelukast Sodium | Montelukast Sodium | 145 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 48 |
| Alendronate Sodium | Alendronate Sodium | 130 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 28 |
| Prednisone | Prednisone | 124 | 46 |
| Trazodone Hcl | Trazodone Hcl | 124 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 27 |
| Allopurinol | Allopurinol | 111 | 28 |
| Famotidine | Famotidine | 104 | 22 |
| Ibuprofen | Ibuprofen | 104 | 53 |
| Atenolol | Atenolol | 99 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 25 |
| Finasteride | Finasteride | 90 | 24 |
| Donepezil Hcl | Donepezil Hcl | 89 | 18 |
| Lorazepam | Lorazepam | 89 | 20 |
| Myrbetriq | Mirabegron | 89 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 86 | 66 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 26 |
| Lovastatin | Lovastatin | 84 | 21 |
| Bupropion Xl | Bupropion Hcl | 82 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 18 |
| Memantine Hcl | Memantine Hcl | 79 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 65 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 26 |
| Buspirone Hcl | Buspirone Hcl | 70 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 69 | 13 |
| Mirtazapine | Mirtazapine | 67 | 16 |
| Benazepril Hcl | Benazepril Hcl | 61 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 16 |
| Synthroid | Levothyroxine Sodium | 57 | 18 |
| Temazepam | Temazepam | 56 | 11 |
| Xarelto | Rivaroxaban | 56 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Baclofen | Baclofen | 53 | 20 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 12 |
| Ezetimibe | Ezetimibe | 50 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 32 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Cephalexin | Cephalexin | 44 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 12 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 28 |
| Ozempic | Semaglutide | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Estradiol | Estradiol | 34 | 13 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 13 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 14 |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 16 |
| Nystatin | Nystatin | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 14 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Ofloxacin | Ofloxacin | 18 | 16 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Klor-Con 8 | Potassium Chloride | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 14 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.52 · 5 records | Abbott Laboratories | EVENITY, FREESTYLE LIBRE 3, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error